GlobeNewsWire
04 Nov 2025, 23:40 UTC · 46w ago
Verdict
Headline takes no side. We score MESO +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA has scheduled a meeting in early December to discuss Mesoblast's data regarding opioid reduction and cessation for rexlemestrocel-L.
More positive than 92% of claims this week
A first Phase 3 study showed patients treated with rexlemestrocel-L were more than 3-fold more likely to cease all opioid use by 36 months compared to controls (p=0.008).
So whatStrong clinical data with statistical significance provides a fundamental valuation basis for the drug's market potential.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Mesoblast is currently recruiting a 300-patient confirmatory Phase 3 trial, with enrollment expected to conclude in the coming quarter.
More positive than 63% of claims this week
Rexlemestrocel-L has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Positive news regarding a scheduled FDA meeting to discuss strong Phase 3 data on opioid cessation and RMAT designation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
10h ago
−1.9%
Price is moving against the score
$15.29 vs $15.59 close before publication (Nov 4) · not market-adjusted
MESO chart →
